Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COSTEM 2021 | The role of ASCT in amyloidosis

Pieter Sonneveld • 6 Oct 2021
COSTEM 2021
Amyloidosis Multiple Myeloma Rare Diseases

Pieter Sonneveld, MD, PhD, Erasmus University, Rotterdam, The Netherlands, comments on the role of autologous stem cell transplantation (ASCT) in the treatment of patients with amyloidosis. Prof. Sonneveld describes how poor tolerability to intensive therapies is a major challenge to ASCT for these patients. Nevertheless, several studies have reported positive results for ASCT. In addition, Prof. Sonneveld describes how novel agents initially developed to treat myeloma have also demonstrated efficacy in amyloidosis. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.

More from Pieter Sonneveld

The PERSEUS trial: primary results of D-VRd vs VRd in newly diagnosed, transplant eligible MM 2:54
The PERSEUS trial: primary results of D-VRd vs VRd in newly diagnosed, transplant eligible MM
Pieter Sonneveld • 11 Dec 2023
Reaching a cure for multiple myeloma
Gareth Morgan et al. • 15 Apr 2023
The benefit of double autologous transplantation in multiple myeloma patient subgroups 1:57
The benefit of double autologous transplantation in multiple myeloma patient subgroups
Pieter Sonneveld • 24 Oct 2022
Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma? 1:27
Do CAR-T therapies play a role in earlier lines of therapy in multiple myeloma?
Pieter Sonneveld • 24 Oct 2022

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals